Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial.

Kansal, Aman; Huang, Zhen; Rockhold, Frank W; Baumgartner, Iris; Berger, Jeffrey S; Blomster, Juuso I; Fowkes, F Gerry; Katona, Brian; Mahaffey, Kenneth W; Norgren, Lars; Hiatt, William R; Patel, Manesh R; Jones, W Schuyler (2019). Impact of Procedural Bleeding in Peripheral Artery Disease: An Analysis From EUCLID Trial. Circulation. Cardiovascular interventions, 12(10), e008069. American Heart Association 10.1161/CIRCINTERVENTIONS.119.008069

[img] Text
CIRCINTERVENTIONS.119.008069.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (390kB) | Request a copy

BACKGROUND The relationship between invasive vascular procedures and bleeding in patients with peripheral artery disease has not been well described in the literature. This post hoc analysis from the EUCLID trial (Examining Use of Ticagrelor in Peripheral Artery Disease) aimed to describe the incidence of major and minor postprocedural bleeding and characterize the timing and severity of bleeding events relative to the procedure. METHODS EUCLID was a multicenter, randomized controlled trial of 13 885 patients with symptomatic peripheral artery disease that tested the efficacy and safety of ticagrelor compared with clopidogrel for the prevention of major adverse cardiovascular events. A total of 2661 patients underwent 3062 coronary revascularization, peripheral revascularization, and amputation during the study. The primary safety end point was Thrombolysis in Myocardial Infarction major or minor bleeding. All bleeding events were formally adjudicated by a clinical end point classification group. RESULTS Major bleeding events most often occurred ≤7 days following the procedure. The incidence of Thrombolysis in Myocardial Infarction major or minor bleeding ≤7 days following peripheral revascularization (3.3%; 95% CI, 2.5%-4.1%) was similar to rates after coronary revascularization (4.0%; 95% CI, 2.6%-5.4%) and lower extremity amputation (2.3%; 95% CI, 0.8%-3.8%). The severity of bleeding events (as graded by drop in hemoglobin, need for transfusion, bleeding in a critical location, and fatal bleeding) was also similar following peripheral, coronary revascularization, and lower extremity amputation. CONCLUSIONS The incidence of Thrombolysis in Myocardial Infarction major/minor bleeding following peripheral revascularization is comparable to rates after coronary revascularization and lower extremity amputation, and the majority of bleeding events occur within 7 days following the procedure. The severity of periprocedural bleeding is also similar after procedures, with the most frequently adjudicated reason being a drop in hemoglobin ≥2 g/dL. Future studies should be performed to enhance our understanding of bleeding risk related to revascularization and amputation procedures in peripheral artery disease patients.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Angiology

UniBE Contributor:

Baumgartner, Iris


600 Technology > 610 Medicine & health




American Heart Association




Catherine Gut

Date Deposited:

14 Jan 2020 15:59

Last Modified:

14 Jan 2020 16:08

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

amputation hemoglobins incidence lower extremity peripheral arterial disease




Actions (login required)

Edit item Edit item
Provide Feedback